Evidence map›Paper›PMID 38654351›Full record

Observational studyCritical care (London, England)2024

Case study observational research: inflammatory cytokines in the bronchial epithelial lining fluid of COVID-19 patients with acute hypoxemic respiratory failure.

Kazuki Sudo, Mao Kinoshita, Ken Kawaguchi, Kohsuke Kushimoto, Ryogo Yoshii, Keita Inoue, Masaki Yamasaki, Tasuku Matsuyama, Kunihiko Kooguchi, Yasuo Takashima and 6 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Critical care (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Kazuki SudoDepartment of Anesthesiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kajiicho 465, Kawaramachi-Hirokoji Agaru, Kamigyo, Kyoto, 602-8566, Japan.
Mao KinoshitaDepartment of Anesthesiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kajiicho 465, Kawaramachi-Hirokoji Agaru, Kamigyo, Kyoto, 602-8566, Japan.
Ken KawaguchiDepartment of Anesthesiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kajiicho 465, Kawaramachi-Hirokoji Agaru, Kamigyo, Kyoto, 602-8566, Japan.
Kohsuke KushimotoDepartment of Anesthesiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kajiicho 465, Kawaramachi-Hirokoji Agaru, Kamigyo, Kyoto, 602-8566, Japan.
Ryogo YoshiiDivision of Intensive Care, Hospital of Kyoto Prefectural University of Medicine, Kajiicho 465, Kawaramachi-Hirokoji Agaru, Kamigyo, Kyoto, 602-8566, Japan.
Keita InoueDivision of Intensive Care, Hospital of Kyoto Prefectural University of Medicine, Kajiicho 465, Kawaramachi-Hirokoji Agaru, Kamigyo, Kyoto, 602-8566, Japan.
Masaki YamasakiDivision of Intensive Care, Hospital of Kyoto Prefectural University of Medicine, Kajiicho 465, Kawaramachi-Hirokoji Agaru, Kamigyo, Kyoto, 602-8566, Japan.
Tasuku MatsuyamaDepartment of Emergency Medicine, Kyoto Prefectural University of Medicine, Kajiicho 465, Kawaramachi-Hirokoji Agaru, Kamigyo, Kyoto, 602-8566, Japan.
Kunihiko KooguchiDivision of Intensive Care, Hospital of Kyoto Prefectural University of Medicine, Kajiicho 465, Kawaramachi-Hirokoji Agaru, Kamigyo, Kyoto, 602-8566, Japan.
Yasuo TakashimaDepartment of Genomic Medical Sciences, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kajiicho 465, Kawaramachi-Hirokoji Agaru, Kamigyo, Kyoto, 602-8566, Japan.
Masami TanakaDepartment of Genomic Medical Sciences, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kajiicho 465, Kawaramachi-Hirokoji Agaru, Kamigyo, Kyoto, 602-8566, Japan.
Kazumichi MatsumotoDivision of Clinical Laboratory, Hospital of Kyoto Prefectural University of Medicine, Kajiicho 465, Kawaramachi-Hirokoji Agaru, Kamigyo, Kyoto, 602-8566, Japan.
Kei TashiroDepartment of Genomic Medical Sciences, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kajiicho 465, Kawaramachi-Hirokoji Agaru, Kamigyo, Kyoto, 602-8566, Japan.
Tohru InabaDivision of Clinical Laboratory, Hospital of Kyoto Prefectural University of Medicine, Kajiicho 465, Kawaramachi-Hirokoji Agaru, Kamigyo, Kyoto, 602-8566, Japan.
Bon OhtaDepartment of Emergency Medicine, Kyoto Prefectural University of Medicine, Kajiicho 465, Kawaramachi-Hirokoji Agaru, Kamigyo, Kyoto, 602-8566, Japan.
Teiji SawaDepartment of Anesthesiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kajiicho 465, Kawaramachi-Hirokoji Agaru, Kamigyo, Kyoto, 602-8566, Japan. anesth@koto.kpu-m.ac.jp.
Kyoto Prefectural University of Medicine · JPKyoto first Red Cross hospital · JP

Funding

Japan Agency for Medical Research and Development JP20fk0108270
6 · The paper itself

Abstract

backgroundIn this study, the concentrations of inflammatory cytokines were measured in the bronchial epithelial lining fluid (ELF) and plasma in patients with acute hypoxemic respiratory failure (AHRF) secondary to severe coronavirus disease 2019 (COVID-19).

methodsWe comprehensively analyzed the concentrations of 25 cytokines in the ELF and plasma of 27 COVID-19 AHRF patients. ELF was collected using the bronchial microsampling method through an endotracheal tube just after patients were intubated for mechanical ventilation.

resultsCompared with those in healthy volunteers, the concentrations of interleukin (IL)-6 (median 27.6 pmol/L), IL-8 (1045.1 pmol/L), IL-17A (0.8 pmol/L), IL-25 (1.5 pmol/L), and IL-31 (42.3 pmol/L) were significantly greater in the ELF of COVID-19 patients than in that of volunteers. The concentrations of MCP-1 and MIP-1β were significantly greater in the plasma of COVID-19 patients than in that of volunteers. The ELF/plasma ratio of IL-8 was the highest among the 25 cytokines, with a median of 737, and the ELF/plasma ratio of IL-6 (median: 218), IL-1β (202), IL-31 (169), MCP-1 (81), MIP-1β (55), and TNF-α (47) were lower.

conclusionsThe ELF concentrations of IL-6, IL-8, IL-17A, IL-25, and IL-31 were significantly increased in COVID-19 patients. Although high levels of MIP-1 and MIP-1β were also detected in the blood samples collected simultaneously with the ELF samples, the results indicated that lung inflammation was highly compartmentalized. Our study demonstrated that a comprehensive analysis of cytokines in the ELF is a feasible approach for understanding lung inflammation and systemic interactions in patients with severe pneumonia.

Indexed as

COVID-19CytokinesRespiratory InsufficiencyAdultAgedBronchiBronchoalveolar Lavage FluidFemaleHumansMaleMiddle AgedCytokinesBronchial microsamplingCOVID-19CytokineEpithelial lining fluidMultiplex bead-based assay

Identifiers

PMID38654351
PMCPMC11036702
OpenAlexW4395047982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.